Dianthus Therapeutics, Inc.
DNTH
$19.84
-$0.11-0.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -28.44M | -25.17M | -17.61M | -13.75M | -10.56M |
| Total Depreciation and Amortization | 78.00K | 289.00K | -62.00K | 107.00K | 103.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.34M | 1.02M | 2.85M | 1.52M | 199.00K |
| Change in Net Operating Assets | -422.00K | 2.60M | 289.00K | -2.82M | -1.59M |
| Cash from Operations | -27.44M | -21.27M | -14.53M | -14.94M | -11.85M |
| Capital Expenditure | -31.00K | -25.00K | -17.00K | -32.00K | -10.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -23.08M | -259.34M | 1.19M | -5.48M | -8.23M |
| Cash from Investing | -23.11M | -259.36M | 1.17M | -5.51M | -8.24M |
| Total Debt Issued | -- | -- | -- | -- | 0.00 |
| Total Debt Repaid | -- | -- | -- | -- | 0.00 |
| Issuance of Common Stock | 39.68M | 296.00K | 47.00K | 230.27M | 0.00 |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | 0.00 | -2.24M | -12.42M | -4.87M |
| Cash from Financing | 39.68M | 296.00K | -2.20M | 217.85M | -4.87M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.88M | -280.34M | -15.56M | 197.40M | -24.96M |